Claritin Extension Should Be Debated As Product-Specific Bill - Barr CEO
Executive Summary
The merits of a patent extension for Schering-Plough's Claritin should be debated in the context of a specific bill for that purpose, Barr CEO Bruce Downey contended at a House Judiciary/Courts & Intellectual Property Subcommittee hearing May 21.